A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

359

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

June 17, 2024

Study Completion Date

July 17, 2024

Conditions
Leiomyosarcoma
Interventions
DRUG

Unesbulin

Unesbulin will be administered as per the dose and schedule specified in the arm description.

DRUG

Dacarbazine

Dacarbazine will be administered as per the dose and schedule specified in the arm description.

OTHER

Placebo

Placebo will be administered as per the schedule specified in the arm description.

Trial Locations (54)

2031

Prince of Wales Hospital, Randwick

2050

Chris O'Brien Lifehouse, Camperdown

3000

Peter MacCallum Cancer Institute, East Melbourne

10027

The Trustees of Columbia University, New York

10060

La Fondazione e l'Istituto di Candiolo, Torino

11101

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

15232

University of Pittsburgh Medical Center, Pittsburgh

19104

University of Pennsylvania, Philadelphia

19144

Thomas Jefferson University, Philadelphia

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

21231

Johns Hopkins Oncology Group, Baltimore

27710

Duke University Medical Center, Durham

28040

Hospital Fundacion Jimenez Diaz, Madrid

32224

Mayo Clinic, Jacksonville

32806

University of Florida (UF) Health Cancer Center - Orlando Health, Orlando

33076

Institut Bergonie, Bordeaux

33612

Moffitt, Tampa

43210

The Ohio State University (OSU), Columbus

48109

University of Michigan, Ann Arbor

60555

Northwestern Medicine - Warrenville Cancer Center, Warrenville

60611

Northwestern Memorial Hospital, Chicago

63110

Washington University, St Louis

68167

Universitaetsmedizin Mannheim, Mannheim

69008

Centre Leon Berard, Lyon

75005

Institut Curie, Paris

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado Denver, Denver

81377

Klinikum der Ludwig-Maximilians-Universitaet Muenchen, München

90024

University of California, Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center, Los Angeles

90403

Sarcoma Oncology Research Center, Santa Monica

91010

City of Hope, Duarte

94305

Stanford Cancer Center, Stanford

97239

Oregon Health & Science University, Portland

06511

Yale University, New Haven

Unknown

Fundacao PIO XII - Hospital de Amor, Barretos

Santa Casa de Misericordia de Porto Alegre, Porto Alegre

Hospital Sao Rafael - Instituto D'Or da Bahia, Salvador

CIP - Centro Integrado de Pesquisas do Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto

Instituto do Cancer do Estado de São Paulo (ICESP), São Paulo

Princess Margaret Hospital, Toronto

Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR), Montreal

Gustave Roussy, Villejuif

Eszak-Pesti Centrumkorhaz - Honvedkorhaz, Budapest

Leids Universitair Medisch Centrum, Leiden

"Niepubliczny Zaklad Opieki Zdrowotnej Zespól Poradni Specjalistycznych TERMEDICA", Poznan

Hospital Universitario Vall d'Hebron, Barcelona

Hospital Universitario 12 de Octubre, Madrid

The Christie NHS Foundation Trust, Manchester

20220-410

INCA I - Instituto Nacional de Cancer, Rio de Janeiro

K1H8L6

The Ottawa Hospital Cancer Centre, Ottawa

02-781

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warsaw

08908

Institut Catala d'Oncologia (Hospital Duran y Reynals), Barcelona

G12 0YN

Beatson, West of Scotland Cancer Centre, Glasgow

SW3 6JJ

Royal Marsden Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PTC Therapeutics

INDUSTRY

NCT05269355 - A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) | Biotech Hunter | Biotech Hunter